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TOPBP1 recruits TOP2A to ultra-ﬁne anaphase
bridges to aid in their resolution
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During mitosis, sister chromatids must be faithfully segregated to ensure that daughter cells
receive one copy of each chromosome. However, following replication they often remain
entangled. Topoisomerase IIa (TOP2A) has been proposed to resolve such entanglements,
but the mechanisms governing TOP2A recruitment to these structures remain poorly
understood. Here, we identify TOPBP1 as a novel interactor of TOP2A, and reveal that it is
required for TOP2A recruitment to ultra-ﬁne anaphase bridges (UFBs) in mitosis. The
C-terminal region of TOPBP1 interacts with TOP2A, and TOPBP1 recruitment to UFBs requires
its BRCTdomain 5. Depletion of TOPBP1 leads to accumulation of UFBs, the majority of which
arise from centromeric loci. Accordingly, expression of a TOPBP1 mutant that is defective in
TOP2A binding phenocopies TOP2A depletion. These ﬁndings provide new mechanistic
insights into how TOP2A promotes resolution of UFBs during mitosis, and highlights a pivotal
role for TOPBP1 in this process.
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F
aithful chromosome segregation is critical in preventing
genome attrition during cell division. This is underscored by
the fact that the mechanisms governing this process are
highly conserved throughout evolution. However, DNA topology
changes during replication and as a result replicated sister
chromatids can remain entwined due to topological constrains,
such as catenation. If not resolved properly, these entanglements
persist during anaphase to form ‘DNA bridges’ between the
separating DNA masses of each daughter cell. These bridges can be
generally divided into two distinct classes based on their ability to
be stained with conventional DNA dyes, that is, stainable ‘anaphase
bridges’ or non-stainable ‘ultra-ﬁne anaphase bridges’ (UFBs)1.
UFBs were ﬁrst identiﬁed as thread-like DNA strands between
daughter DNA masses, generally not stained by conventional
DNA dyes but coated with the Bloom syndrome helicase (BLM)
protein, as observed by immunoﬂuorescence analyses1. BLM is a
member of the RecQ helicase family, and mutations in this gene
result in Bloom syndrome, a condition characterized by cancer
predisposition and developmental abnormalities2. Subsequently,
the Polo-like kinase-interacting checkpoint helicase (PICH) was
also shown to localize to these UFBs where it co-localizes with
BLM3. It was also demonstrated that PICH binding to UFBs
results from the DNA substrate undergoing tension and
stretching4, and that PICH association to UFBs is required for
BLM recruitment5.
A subset of UFBs arise from common genomic fragile sites,
which can be induced by replication stress, for example,
treatment with aphidicolin6. They most likely result from sister
chromatid interlinks generated by unresolved replication
intermediates, and are characterized by the presence of the
Fanconi Anaemia (FA) protein FANCD2 forming foci localizing
at either end of the bridge6. In addition, gH2AX foci are detected
at the extremities of these bridges as mitosis progresses,
suggesting induction of a DNA damage response6. Recently,
elegant work from two groups has shown that resolution of these
structures is an active, MUS81–EME1-dependent process7,8.
However, the majority of UFBs do not associate with the FA
proteins, and the mechanism governing their resolution remains
more enigmatic9. These UFBs originate mainly from centromeric
loci in the genome, which suggests that they arise from
unresolved DNA catenanes of fully replicated DNA strands
present in anaphase3,9. They diminish in number upon
progression through mitosis, and DNA double-strand breaks
are not readily detectible in the daughter cells9. This suggests that
they must be decatenated by the end of mitosis presumably by
topoisomerases, most likely topoisomerase IIa (TOP2A), as
TOP2A is the main enzyme involved in removal of DNA
catenation in vertebrates. Accordingly, treatment with TOP2A-
speciﬁc inhibitor, ICRF-193 or razoxane, which locks the enzyme
in the so-called ‘closed-clamp’ form, preventing disjunction of
catenated sister duplexes, leads to an increase in centromeric-
associated UFBs (C-UFBs)1,3. Interestingly, cohesin persists at the
centromere until anaphase onset and can act as a physical barrier
to TOP2A, thus cohesin removal is also required for chromatid
decatenation10. However, the mechanism of TOP2A recruitment
to these structures or in fact, any role in their resolution is unclear
and remains a key question in the ﬁeld9.
Topoisomerase IIb-binding protein 1 (TOPBP1) was initially
identiﬁed in a yeast two-hybrid screen for factors interacting with
the C-terminal region of DNA topoisomerase-IIb11. TOPBP1 is a
large, highly conserved, BRCT-domain-containing protein, with a
crucial role in promoting efﬁcient initiation of DNA replication,
as well as the cellular response to replicative stress12–14. TOPBP1
is also necessary for proper mitotic progression15 and has recently
been shown to localize to UFB-like structures in yeast and
transformed chicken cell lines16.
Here we identify TOPBP1 as a novel interactor of TOP2A that
is required to promote the resolution of C-UFBs. We establish
that this interaction is highly enriched in the G2/M phase of the
cell cycle, requires the C-terminal region of TOPBP1 and is
essential for efﬁcient resolution of C-UFBs. On the basis of these
ﬁndings, we propose that TOPBP1 recruits TOP2A to UFBs to
aid resolution of DNA entanglements between sister chromatids,
and this function could contribute to the role that these proteins
play in the maintenance of genome stability.
Results
TOPBP1 is a novel TOP2A-interacting protein. To understand
the mechanism of TOP2A recruitment to UFBs, we undertook an
unbiased proteomic approach to map TOP2A’s protein–protein
interactions. To this end, we performed immunoprecipitation
(IP) experiments followed by mass spectrometry (IP/MS) analysis
of TOP2A-associated proteins from HEK293 cells enriched in
G2/M phase. Among known interactors including TOP1 (ref. 17),
XRCC5 (ref. 18), the FACT complex subunit SSRP1 (ref. 19),
Aurora B kinase20, HDAC1 (ref. 21), DDX21 (ref. 19) and
CDC5L22, we also identiﬁed TOPBP1 as a novel putative TOP2A-
binding partner (Fig. 1a). Given that TOPBP1/Dpb11 has been
recently shown to localize to UFBs, we set out to validate this
interaction16. First, we immunoprecipitated green ﬂuorescent
protein (GFP)–TOPBP1 from nocodazole-treated or asyn-
chronous U2OS cells stably expressing this fusion protein at a
level similar to that of the endogenous protein (Fig. 1b). We could
readily detect endogenous TOP2A by western blotting of
GFP–TOPBP1 immunoprecipitates in G2/M enriched cells
(Fig. 1b). Accordingly, endogenous TOPBP1 was detected in
reciprocal GFP–TOP2A immunoprecipitates from cell extracts
(Fig. 1c), thus conﬁrming that the two proteins likely exist in the
same complex in cells. Enrichment in G2/M phase in all cases was
determined by ﬂuorescence-activated cell sorting analysis
(Supplementary Fig. 1a). Thus far, TOPBP1 localization to
UFBs has been reported only in yeast Saccharomyces cerevisiae
and the transformed avian B-lymphoblastoid cell line DT40
(ref. 16). Therefore, we decided to test whether this was also the
case in human transformed and importantly, primary cells. We
found by antibody staining and immunoﬂuorescence microscopy
that in U2OS cells undergoing mitosis, TOPBP1 protein localized
to ‘thread-like’ structures forming a bridge linking the daughter
DNA masses in anaphase and early telophase cells (Fig. 1d). To
verify that these were indeed UFBs, we counterstained the cells
with an antibody directed against BLM, a known marker of UFBs,
where a subset of TOPBP1 bridges also stained for BLM on the
same bridge (Fig. 1e). Next, we validated that this localization was
not an antibody-based artefact by reproducing this observation in
U2OS cells stably expressing GFP–TOPBP1 (Supplementary
Fig. 1b). We also conﬁrmed this observation in another human
cell line (HeLa cells, Fig. 1f) and importantly, in a human primary
cell line (human dermal ﬁbroblasts, Fig. 1g). Taken together,
these data support the notion that TOPBP1 plays an
evolutionarily conserved role in sister chromatid disjunction,
and importantly demonstrates that this localization is likely to
represent a physiological process associated with normal cell
division. Interestingly, TOPBP1 seemed to stain only a part of the
bridge and its co-localization with BLM is rare (Fig. 1e).
TOPBP1 localization to UFBs is mediated via its BRCT 4 and 5.
TOPBP1 carries out most of its functions via nine BRCT domains
that mediate phosphorylation-dependent protein–protein inter-
actions in several distinct complexes23. Importantly, only the
BRCT domains 1/2 and 4/5 are conserved between yeast and
human24. As TOPBP1’s yeast orthologue has been shown to
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Figure 1 | TOPBP1 is a novel TOP2A-interacting protein that localizes to UFBs. (a) Proteins identiﬁed in IP/MS analysis of GFP-Trap puriﬁcation from
HEK 293FT cells expressing GFP–TOP2A. (b) Endogenous TOP2A co-immunoprecipitates with GFP-tagged TOPBP1. U2OS control cells or U2OS cells
stably expressing GFP–TOPBP1 were untreated or treated with nocodazole (0.1mgml 1 for 16 h) as indicated, and subjected to GFP-nanotrap
immunoprecipitation. Input¼0.4% of total IP. (c) Endogenous TOPBP1 co-immunoprecipitates with GFP-tagged TOP2A. U2OS control cells or U2OS cells
stably expressing GFP–TOP2A were treated with nocodazole (0.1mgml 1 for 16 h) and subjected to GFP-nanotrap immunoprecipitation. Input¼0.4% of
total IP. (d,e) Immunoﬂuorescence microscopy in U2OS cells with antibodies against TOPBP1; BLM serves as a positive control. DAPI serves as a DNA
stain. (f) Immunoﬂuorescence microscopy of HeLa cells with antibodies against TOPBP1. DAPI serves as a DNA stain. (g) Immunoﬂuorescence in human
primary cells (human dermal ﬁbroblasts) using antibody against TOPBP1. DAPI serves as a DNA stain. Scale bar, 6.4 mm.
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localize to UFBs16, we hypothesized that these conserved BRCT
domains may mediate its localization to UFBs in human cells.
To test this, we generated pools of U2OS cells stably expressing
GFP-tagged TOPBP1 BRCT1 and BRCT5 mutant proteins, with
highly conserved lysine residues binding the phosphate group of
the modiﬁed ligand, mutated to alanine (Fig. 2a), as we
considered these domains as most likely to mediate TOPBP1’s
interactions/recruitment25–27. We found that only the K704A
TOPBP1 BRCT5 mutant protein was defective in its localization
to UFBs in the absence of endogenous TOPBP1, with no defect
observed for the GFP–TOPBP1 wild type (WT) or the GFP–
TOPBP1 K154A-expressing cells (Fig. 2b–d; Supplementary
Fig. 2a–c). To validate these data, we analysed single clones
stably expressing the TOPBP1 mutant proteins. Again we found
that only the BRCT domain-5 (K704A) mutant of TOPBP1 was
defective in its localization to UFBs in the absence of endogenous
TOPBP1, with no defect observed for the cells expressing
GFP–TOPBP1 WT or GFP–TOPBP1 K154A (Fig. 2e,f;
Supplementary Fig. 2d–f). Moreover, and in support of the data
above mutating the BRCT5 Lys704 to glutamic acid (K704E) also
resulted in a profound defect in the ability of this mutant protein
to localize to UFBs in the absence of endogenous TOPBP1
(Fig. 2g; Supplementary Fig. 2g). In addition, given that BRCT
domains interact with phosphorylated proteins, this suggested
that a phosphorylated residue in a TOPBP1-interacting protein
might mediate such localization.
BRCT5 of TOPBP1 mediates a phospho-dependent interaction
between TOPBP1 and the BLM helicase, phosphorylated on
Ser304 (ref. 28). Given the above and the fact that BLM localizes
to UFBs, we considered the possibility that TOPBP1/BLM
localization to these structures could be interdependent. To test
this hypothesis, we analysed whether the BLM–TOPBP1 inter-
action was required to promote their recruitment to UFBs.
However, BLM depletion had no discernable effect on the ability
of TOPBP1 to localize to UFBs (Supplementary Fig. 3a),
suggesting that BLM is not required for its recruitment to UFBs.
BRCT domain 5 has been reported to mediate the interaction
between TOPBP1 and MDC1, as well as 53BP1 (refs 29,30).
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Figure 2 | BRCT5 of TOPBP1 mediates its recruitment to UFBs. (a) Schematic representation of GFP–TOPBP1 mutant constructs used in this study
(WT TOPBP1, BRCT1—K154A; BRCT5—K704A). (b–d) Quantiﬁcation of GFP–TOPBP1 WT, K154A and K704A mutant localization to UFBs in pools of
U2OS cells stably expressing GFP–TOPBP1 WT or mutant proteins (endogenous TOPBP1 was knocked down using siRNA directed against the 30 UTR
(si TOPBP1); scrambled pool siRNA was used as a control (si Control)). Mean from three independent experiments is depicted with bars representing
±s.e.m. At least 50 ana/telophase cells were scored per experiment and the w2-test was used to determine statistical signiﬁcance. (e–g) Analysis of
localization of GFP–TOPBP1 WT, K704A and K704E mutants to UFBs in single U2OS clones expressing GFP–TOPBP1 WTor mutant proteins (endogenous
TOPBP1 was depleted using siRNA directed against the 30 UTR (si TOPBP1); scrambled pool siRNA was used as a control (si Control)).
Mean from three independent experiments is depicted with bars representing±s.e.m. At least 50 ana/telophase cells were scored per experiment and the
w2-test was used to determine statistical signiﬁcance.
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Given that both these proteins associate with chromatin and
promote TOPBP1 chromatin localization29,30, we considered
the possibility that they may somehow promote TOPBP1
recruitment to UFBs. To test this, we knocked down MDC1
and 53BP1 and then analysed the kinetics of TOPBP1
recruitment to UFBs. We found that neither MDC1 nor 53BP1
knockdown had a major effect on TOPBP1 localization to UFBs
(Supplementary Fig. 3b,c). Taken together, these data suggest that
BLM, MDC1 and 53BP1 do not play a major role in TOPBP1
recruitment to UFBs.
Finally, we also tested whether PICH depletion could result in
deﬁcient TOPBP1 localization to UFBs, as this protein is thought
to be one of the ﬁrst factors localizing to UFBs5. Again, knocking
down PICH had no effect on TOPBP1 localization to UFBs,
but as expected did cause a reduction in the incidence of
BLM-positive UFBs (Supplementary Fig. 3d,e)5. In summary, this
suggests that TOPBP1 localization to UFBs is most likely
dependent on an as yet unidentiﬁed BRCT5-interacting protein.
Given that TOPBP1 was identiﬁed on the basis of its
association with the C terminus of TOP2B in a yeast two-hybrid
screen, we considered the possibility that TOP2B may impact on
the resolution of UFBs. To this end, we depleted TOP2B in U2OS
cells and analysed the frequency of TOPBP1 and BLM UFBs. In
line with TOP2B being non-essential for decatenation of DNA
and progression through mitosis31,32, we found no signiﬁcant
change in the frequency of either type of UFBs (Supplementary
Fig. 3f–h).
The majority of TOPBP1-coated UFBs arise from centromeres.
UFBs can arise as a result of either decatenation or replication
problems1,9. Given that we identify TOPBP1 as a novel TOP2A
interactor, and that inhibition of TOP2A leads to an increase in
C-UFBs3,9, we hypothesized that TOPBP1 may localize to this
subtype of UFBs. To test this, we analysed the frequency
of TOPBP1-coated UFBs in cells treated with aphidicolin,
a potent DNA replication inhibitor, and razoxane, a speciﬁc
topoisomerase II inhibitor3,9. Upon treatment with razoxane, but
not aphidicolin, we could detect an increase in the percentage of
ana/telophase cells with TOPBP1 UFBs (Fig. 3a,b). As an
additional control to validate the efﬁcacy of aphidicolin and
razoxane treatment, we analysed the incidence of BLM UFBs
under these experimental conditions. In line with previous
reports and in support of the notion above, we observed a
signiﬁcant increase in BLM-positive UFBs upon drug treatment
(Fig. 3c; Supplementary Fig. 4a,b)3,9. Moreover, treatment with
another TOP2A inhibitor ICRF-193 also resulted in an increased
frequency of TOPBP1 UFBs with a concomitant increase in BLM
UFBs (Supplementary Fig. 4c,d). This suggests that TOPBP1 is
speciﬁcally recruited to UFBs arising as an effect of TOP2A
inhibition. Moreover, the amount of TOPBP1 UFBs co-staining
with BLM also increased following razoxane, but not with
aphidicolin treatment (Supplementary Fig. 4e,f). TOP2A
depletion and/or inhibition speciﬁcally increases the frequency
of C-UFBs1,3, therefore if our hypothesis was correct then
depletion of TOP2A should also result in an increased frequency
of TOPBP1 UFBs, and indeed this is exactly what we observed
(Fig. 3d; Supplementary Fig. 4g). Importantly, this was also
accompanied by an increase in BLM UFBs as well as 40,6-
diamidino-2-phenylindole (DAPI)-positive anaphase bridges
(Fig. 3e,f), a previously characterized phenotype of TOP2A
deﬁciency3,9,16. Since treatment with the replication inhibitor
aphidicolin did not increase the frequency of TOPBP1 UFBs but
TOP2A depletion or inhibition did, these data suggest that
TOPBP1 predominately associates with UFBs arising from
centromeric loci (C-UFBs). These are most likely derived from
problems associated with decatenation of sister chromatids and
would require TOP2A for their resolution.
To further explore the role of TOPBP1 in promoting resolution
of C-UFBs, it was important to establish the consequences of
TOPBP1 depletion on their resolution. To this end, we depleted
TOPBP1 by short interfering RNA (siRNA) and analysed the
frequency of BLM-positive UFBs. Upon TOPBP1 depletion, we
detected a signiﬁcant increase in the number of cells with BLM
UFBs (Fig. 4a). One prediction from this notion would be that the
TOPBP1 mutant defective in its association with UFBs (BRCT5
mutant) should display the same phenotype. In line with this, we
detected a statistically signiﬁcant increase in the number of BLM-
positive UFBs in cells expressing this mutant protein, while cells
expressing WT GFP–TOPBP1 (in the absence of endogenous
TOPBP1) show no such increase under the same conditions
(Fig. 4a), further validating the functionality of this fusion
protein. Next, we addressed whether a physical link between these
induced UFBs and centromeric DNA can be established. To do
so, we stained cells for BLM and a centromeric marker, CENPB.
Strikingly, the majority of the UFBs induced in the absence of
TOPBP1 stained positive for CENPB (Fig. 4b,c), thus supporting
the idea that TOPBP1 associates predominately with C-UFBs.
Taken together, these data support a role for TOPBP1 in
promoting chromosome disjunction by aiding resolution of
C-UFBs. Moreover, BLM recruitment to UFBs seems to be
TOPBP1-independent.
TOPBP1 interacts with TOP2A via its C terminus. To gain
further insight into the potential functional relevance of the
TOPBP1–TOP2A interaction, we designed a series of GFP-tagged
TOPBP1 truncation constructs that sequentially removed single
or tandem BRCT domains (Fig. 5a). We conﬁrmed the efﬁcacy of
this approach by assaying their ability to interact with previously
reported TOPBP1-binding partners (Supplementary Fig. 5a).
Signiﬁcantly, a TOPBP1 truncation mutant lacking the ATR-
activation domain as well as the BRCT7 and 8 domains displayed
no detectable binding to the endogenous TOP2A (Fig. 5b). To
further map the minimal binding region, we generated TOPBP1
construct lacking only BRCT7 and 8 and found that this mutant
was also defective in its interaction with TOP2A (Fig. 5c;
Supplementary Fig. 5b, BLM and FANCJ were used as internal
controls for this construct). This suggests that the extreme C
terminus of TOPBP1 mediates its interaction with TOP2A.
Recently, both TOP2A and TOPBP1 have been reported to
interact with components of the BRG1- or HRBM-associated
factors (BAF) complex therefore, we tested whether BRG1 (the
subunit of this complex that interacts with TOPBP1) promotes
the TOP2A–TOPBP1 interaction33,34. However, knocking down
BRG1 did not abrogate TOPBP1–TOP2A interaction (Supple-
mentary Fig. 6), suggesting that the two proteins interact directly
or via another partner.
TOPBP1 is required for TOP2A recruitment to UFBs. Next, to
address whether TOPBP1 promotes recruitment of TOP2A to
UFBs to promote their decatenation, it was important to establish
whether TOP2A and TOPBP1 co-localize on these structures. To
this end, we optimized the recently developed proximity ligation
assay (PLA) that allows the detection of protein–protein inter-
actions at the single-molecule level by immunoﬂuorescence
microscopy35. Using this approach and employing antibodies
directed against endogenous TOPBP1 and TOP2A, we were able
to visualize co-localization of TOPBP1 and TOP2A on UFBs
(Fig. 6a,b; Supplementary Fig. 7a; these cells stably express GFP–
TOPBP1, which serves as a marker of UFBs). Importantly, the
majority of GFP–TOPBP1 UFBs observed were also associated
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with the PLA signal (co-localizing TOP2A–TOPBP1) (Fig. 6c).
No PLA signal was observed in the negative control (Fig. 6c).
Moreover, and in support of our hypothesis the TOPBP1 BRCT7/
8 truncation mutant unable to bind TOP2A (Fig. 5c) showed
defective co-localization of TOPBP1–TOP2A on UFBs, as assayed
by the PLA technique (Fig. 6d,e). To our knowledge, this is the
ﬁrst time that TOP2A localization to UFBs has been observed.
Given the above and the facts that (i) these two proteins co-
immunoprecipitate in a cell enriched in the G2/M phase of the
cell cycle and (ii) TOPBP1 depletion leads to the accumulation of
C-UFBs, we hypothesized that TOPBP1 promotes recruitment of
TOP2A to UFBs thereby aiding their resolution.
If the above were correct then one would expect that cells
expressing a mutant protein defective for TOPBP1–TOP2A
interaction would display aberrant resolution of UFBs and
increased incidence of DAPI-positive anaphase bridges, as
observed in TOP2A-depleted cells (Fig. 3e,f and ref. 36). We
tested this hypothesis using TOPBP1 mutant defective in TOP2A
interaction, but proﬁcient in UFB localization (Figs 5c and 6d). In
support of our line of thinking, cells expressing this TOPBP1
mutant protein phenocopied TOP2A depletion showing a
signiﬁcant increase in the incidence of both BLM UFBs as well
as DAPI-positive anaphase bridges, as compared with mock-
transfected control cells and cells expressing GFP–TOPBP1 WT
(Fig. 7a–c). Moreover, the majority of these induced BLM UFBs
emanated from centromeric loci, as assayed by CENPB staining
(Supplementary Fig. 7b). Taken together, our data support a
model whereby TOPBP1–TOP2A interaction promotes recruit-
ment of TOP2A to centromeric UFBs to aid their resolution
(Fig. 7d).
Discussion
During every cell cycle DNA must be faithfully replicated and
segregated to ensure that each daughter cell receives a copy of
every chromosome. However, DNA topology changes during
replication and as a result of this replicated sister chromatids
remain entangled (catenated). The function of DNA catenation is
not well understood but has been implicated in both sister
chromatid cohesion and chromosome condensation37. What is
clear, however, is the fact that for cells to undergo successful
mitosis the DNA intertwining between sister chromatids needs to
be completely removed. This process is thought to be regulated
by DNA topoisomerase II type enzymes, and in particular
TOP2A31,32. However, the experimental evidence for this as well
as the possible mechanism governing TOP2A recruitment to
UFBs remains enigmatic.
In this study, we ﬁnd that TOPBP1, a multifunctional
replication/checkpoint protein, is a novel TOP2A interactor
mediating its localization to UFBs originating from centromeric
loci. To shed light on the mechanism of TOPBP1 recruitment to
UFBs, we map the minimal region required for its localization to
UFBs to BRCT motifs 4 and 5. Importantly, and in support of its
role in UFBs’ resolution we show that depletion of TOPBP1, or
mutation within the highly conserved lysine residue (K704) of the
BRCT5, results in a sharp increase in the incidence of C-UFBs in
the absence of endogenous TOPBP1. Replication inhibition
increases the frequency of UFBs; however, the C-UFBs are
thought not to contain aberrant DNA structures36. Since
TOPBP1 depletion induces UFBs that primarily associate with
the centromeric marker CENPB, we consider it unlikely that it is
TOPBP1’s function in replication/checkpoint activation that
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Figure 3 | TOP2A inhibition or depletion results in increased TOPBP1 localization to UFBs. (a,b) Quantiﬁcation of the percentage of ana/telophase cells
staining positive for TOPBP1 localization to UFBs in U2OS cells treated for 24 h with dimethylsulphoxide (DMSO) as a control, or with 0.4 mM aphidicolin
(APH) or 10mM razoxane (RAZ). Bars represent mean values from three independent experiments±s.e.m. At least 50 ana/telophase cells were scored
per experiment and the w2-test was used to determine statistical signiﬁcance. (c) Quantiﬁcation of the percentage of U2OS ana/telophase cells staining
positive for BLM UFBs in cells treated for 24 h with DMSO as a control or with 0.4mM APH. Bars represent mean values from three independent
experiments ±s.e.m. A minimum of 50 ana/telophase cells were scored per experiment, the w2-test was used to determine statistical signiﬁcance.
(d) Quantiﬁcation of the percentage of U2OS cells positive for TOPBP1 UFBs in cells treated with siRNA targeting TOP2A or in control siRNA-treated cells.
Mean from three independent experiments with bars indicating±s.e.m. At least 50 ana/telophase cells were scored per experiment, the w2-test was used
to determine statistical signiﬁcance. (e,f) Quantiﬁcation of the percentage of U2OS cells positive for BLM UFBs and DAPI-positive anaphase bridges,
respectively. Cells were treated with siRNA directed against TOP2A or control siRNA. Mean from three independent experiments with bars indicating
±s.e.m. At least 50 ana/telophase cells were scored per experiment; the w2-test was used to determine statistical signiﬁcance.
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drives this phenotype. This supports the idea that UFBs that
require the action of TOPBP1 most likely originate from
unresolved DNA catenanes that physically link sister
chromatids, and have to be resolved before DNA segregation
can take place. In support of this line of thinking, we show that
treatment with TOP2A-speciﬁc inhibitors, but not DNA
replication inhibitor aphidicolin, increases the number of
TOPBP1-stained UFBs. Likewise, depletion of yeast TOP2
increases the frequency of DPB11/TOPBP1-coated UFBs,
whereas aphidicolin treatment in both yeast as well as avian
DT40 cells does not16. Moreover, C-UFBs generally are thought
not to contain single-stranded DNA36, and in support of our
hypothesis in chicken cells only a small proportion of TOPBP1
UFBs stain for RPA, a marker of single-stranded DNA16.
Nevertheless, it is possible that TOPBP1 binds more than one
type of bridge. However, we think that the majority that are
stained with TOPBP1 are centromeric.
Our in vivo mapping shows that TOPBP1 localization to UFBs
requires its BRCT domain 5, and is most likely phospho-
dependent. This is based on the fact that mutating Lys704, which
directly contacts the phosphate group of the cognate binding
partner30,38, to either alanine or glutamic acid abrogates TOPBP1
recruitment to UFBs. However, our data also show that none of
the known TOPBP1 BRCT5-interacting proteins mediate its
recruitment to UFBs. This is based on the observations that
depletion of BLM, MDC1 or 53BP1 does not affect TOPBP1
recruitment to UFBs. Likewise, depleting TOPBP1 does not
abrogate BLM recruitment. On the basis of the above, we
conclude that TOPBP1 recruitment to UFBs is most likely
independent of these proteins. This raises the question as to how
TOPBP1 is being recruited to UFBs. TOPBP1 displays DNA-
binding activity in vitro39 therefore, it is possible that perhaps
exposed DNA present within the UFBs acts as a substrate for
TOPBP1 binding. Another possibility, which seems more likely, is
that a phosphorylated residue on an as yet unidentiﬁed protein
mediates this interaction.
Interestingly, we noticed that a small proportion of BLM-
positive bridges could be also stained for TOPBP1. Intriguingly,
in the majority of such cases TOPBP1 stains only part of the
bridge. It is unclear at present what would be the physiological
relevance of this. It is tempting to hypothesize that TOPBP1 is
recruited to promote resolution of centromeric DNA catenations
early in mitosis, thereby promoting sister chromatid disjunction.
Upon progression to anaphase, DNA entanglements that have
not been resolved in a timely manner, may lead to formation of
DNA bridges (which would be stained by TOPBP1). Subse-
quently, DNA tension would increase creating a substrate
recognized by PICH, and this will allow for BLM loading on
these structures4,5. TOPBP1 may promote decatenation of such
structures, thus relieving the tension on the DNA strands. This in
turn could result in dissociation of PICH and hence BLM, with
TOPBP1 possibly remaining. This hypothesis is supported by the
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Figure 4 | TOPBP1 depletion impedes C-UFBs resolution. (a) Quantiﬁcation of BLM-positive UFBs in control U2OS cells or cells stably expressing
GFP–TOPBP1 WTor GFP–TOPBP1 K704E, respectively, in the presence or absence of endogenous TOPBP1. Mean from three independent experiments with
bars indicating±s.e.m. A minimum of 50 ana/telophase cells were scored per experiment and the w2-test was used to determine statistical signiﬁcance.
(b) Quantiﬁcation of UFBs emanating from centromeric loci, as assayed by CENPB staining in TOPBP1-depleted cells. Mean from three independent
experiments with bars indicating±s.e.m. A minimum of 50 ana/telophase cells were scored per experiment. (c) Representative image of an anaphase cell
with a BLM-positive UFB (red) that emanates from a CENPB focus (green). DAPI (blue) serves as a DNA stain. Scale bar, 6.4 mm.
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observation that the incidence of TOPBP1 on UFBs also staining
for BLM is increased upon inhibition or depletion of TOP2A, and
the fact that TOPBP1 recruitment to UFBs is BLM-independent.
This could also account for the UFBs we observe staining positive
for TOPBP1 but not BLM.
Finally, in support of TOPBP1’s putative role in promoting
recruitment of TOP2A to UFBs associated with centromeric loci,
we not only determined that this interaction is highly enriched in
G2/M phase, but also crucially visualize co-localization of
TOPBP1 with TOP2A on UFBs. Moreover, expression of a
TOPBP1 mutant no longer able to bind TOP2A resulted in a
decrease in co-localization of TOP2A to TOPBP1 UFBs, as
measured by the PLA technique. Moreover, it also led to a sharp
increase in UFBs as well as DAPI-positive bridges and as such, it
phenocopied TOP2A depletion.
On the basis of the above ﬁndings, we propose the following
possible mechanism for TOPBP1-dependent resolution of
UFBs (Fig. 7d). TOPBP1 is recruited to UFBs via its intrinsic
DNA-binding activity or by interaction with a phosphorylated
amino acid from an as yet unidentiﬁed partner. This provides a
binding platform for TOP2A recruitment to UFBs that is
mediated via the C-terminal region of TOPBP1. This in turn
promotes efﬁcient TOP2A-dependent decatenation of sister
chromatids before they are segregated during the ﬁnal stages of
mitosis.
TOP2A is an essential enzyme with fundamental role in
regulating DNA topology40. Overexpression/ampliﬁcation of
TOP2A is characteristic of many tumours and negatively
correlates with patients’ survival41,42. This work provides an
important molecular insight into the mechanism of TOPBP1–
TOP2A interaction and resolution of the most prevalent class of
UFBs (C-UFBs). Given that drugs targeting TOP2A, such as
TOP2A poisons, are commonly used in anticancer treatment43, it
is conceivable therefore, that the interaction described here could
provide a framework for further studies aiming towards
development of novel anticancer therapeutic approaches.
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Methods
Cell lines and chemicals. HEK 293FT, HeLa and U2OS cells were a kind gift from
Dr G. Stewart and Dr F. Esashi, respectively, and were cultured in DMEM con-
taining 10% fetal bovine serum (FBS) and 1% of antibiotics solution (penicillin and
streptomycin, Lonza)44. Primary dermal ﬁbroblasts from neonatal human foreskin
were purchased from CELLnTEC Advanced Cell Systems and cultured in MEM
media supplemented with 10% FBS and 1% of antibiotics solution (penicillin and
streptomycin, Lonza), as previously described45,46. Stable cell lines were generated
by transfection with indicated constructs and maintained in media supplemented
with 500 mgml 1 G-418 followed by clonal selection. All chemicals were from
Sigma-Aldrich, unless otherwise stated.
SDS–PAGE and western blotting. Primary antibodies and dilutions used in the
outlined western blotting experiments were 53BP1 (MAB3802, Millipore, 1:3,000),
a-tubulin (T5168, Sigma, 1:30,000), BLM (A300-110A, Bethyl Laboratories,
1:2,000), BRG1 (sc-10768, Santa Cruz Biotechnology, 1:200), FANCJ (B1310,
Sigma, 1:5,000), GFP (11814460001, Roche, 1:1,000), MDC1 (obtained from
Dr G. Stewart, University of Birmingham, 1:1,000 (ref. 47)), PICH (04–1540,
Millipore, 1:1,000), Rad9 (R7404, Sigma, 1:1,000), TOP2A (TG2011-1, Topogen,
1:1,000), TOP2B (ab58442, Abcam, 1:1,000) and TOPBP1 (A300-111A, Bethyl
Laboratories, 1:5,000). SDS–PAGE and western blotting were performed as
described previously48.
Plasmids and transfections. Plasmid construct encoding human GFP–TOPBP1
in pIRESneo2 (Clontech) vector backbone was obtained from Professor T.D.
Halazonetis30. GFP–TOPBP1 truncation mutants or point mutants were generated
by site-directed mutagenesis. Plasmid construct coding for human GFP–TOP2A in
pEGFPC3 (Clontech) plasmid backbone49 was obtained from Dr G.J. Gorbsky.
GFP–TOP2A truncation mutants were generated by site-directed mutagenesis.
Plasmids were transfected into human cells using Lipofectamine 2000 (Life
Technologies), according to the manufacturer’s instructions.
RNA interference treatment. siRNAs targeting human 53BP1 (sc-37455) and
BRG1 (sc-29827) and TOP2A (sc-36695) were obtained from Santa Cruz Bio-
technology. siRNA pools targeting MDC1 (L-003506-00) and PICH (L-031581-01)
were obtained from Dharmacon. Oligonucleotide mix targeting the 30 untranslated
region (UTR) of endogenous human TOPBP1 (Dharmacon) contained the fol-
lowing oligos: 50-GUAAAUAUCUGAAGCUGUAUU-30, 50-GCACAAGGUUUA
AUGAGGAUU-30 , 50-GCUGUAGCUUAGUGGAAAUUU-30. The oligonucleo-
tide targeting the 30 UTR of BLM (Dharmacon) was as follows: 50-GCUAGGAGU
CUGCGUGCGAUU-30 . siRNA targeting TOP2B was 50-UCGGGCUAGGAAAG
AAGUAAA-30 (ref. 50): Santa Cruz Biotechnology non-targeting siRNA control
(sc-37007) or Dharmacon non-targeting smart pool siRNA (D-00180-10-20) were
used as control siRNAs where appropriate. Oligonucleotides were transfected into
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Figure 6 | TOP2A localizes to UFBs. (a) Schematic describing the proximity ligation assay (PLA) employed to visualize TOPBP1–TOP2A co-localization on
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human cells using Oligofectamine reagent (Life Technologies), according to the
manufacturer’s instructions.
Co-immunoprecipitations. For preparation of lysates for co-immuno-
precipitations, cells were washed twice in phosphate-buffered saline and lysed
in IP buffer (100mM NaCl, 0.2% Igepal CA-630, 1mM MgCl2, 10% glycerol,
5mM NaF, 50mM Tris-HCl, pH 7.5), supplemented with complete EDTA-free
protease inhibitor cocktail (Roche) and 25Uml 1 Benzonase (Novagen).
After nuclease digestion, NaCl and EDTA concentrations were adjusted to 200
and 2mM, respectively, and lysates were cleared by centrifugation (16,000 g
for 25min). Lysates were then incubated with 20 ml of GFP-Trap agarose
beads (ChromoTek) for 2 h with end-to-end mixing at 4 C. Complexes were
washed extensively before resuspension in 2 SDS sample buffer. Examples of
full gel immunoblots from IP experiments are presented in Supplementary Figs 8
and 9.
For MS analyses, eluates from IP experiments were analysed by the Mass
Spectrometry Laboratory (IBB PAS, Warsaw, Poland) using the Thermo Orbitrap
Velos system, and protein hits were identiﬁed by MASCOT.
Immunoﬂuorescence microscopy. Antibodies employed for immunoﬂuorescence
were as follows: BLM (sc-7790, Santa Cruz Biotechnology, 1:100), CENPB
(ab25734, Abcam, 1:1,000), GFP (11814460001, Roche, 1:500 or 598, MBL, 1:500),
TOP2A (MAB4197, Millipore, 1:1,000) and TOPBP1 (A300-111A, Bethyl
Laboratories, 1:200). Mitotic cells were enriched by mitotic shake-off and
centrifuged at 1,000 g for 3min onto poly-L-Lysine slides (Thermo Scientiﬁc).
Slides were ﬁxed in 100% methanol for 20min at  20 C and blocked in 10% FBS
in PBS for 30min before incubation with indicated primary antibodies (in 0.1%
FBS in PBS) for 1 h at room temperature. Unbound primary antibodies were
removed by washing 4 5min in PBS at room temperature followed by incubation
with indicated secondary antibodies for 45min at room temperature. Slides were
then washed 4 5min in PBS before mounting with Vectashield mounting
medium (Vector Laboratories) with DAPI. For PLAs, antibodies against TOPBP1
(A300-111A, Bethyl Laboratories, 1:200) or GFP (598, MBL, 1:500) and TOP2A
(MAB4197, Millipore, 1:1,000) were used with the Duolink In Situ Starter Kit
(DUO92101-1KT, Sigma) according to the manufacturer’s recommendations.
Images were acquired with a Zeiss Observer Z1 microscope using an X40 objective
and ZEN 2012 (blue edition) software (Carl Zeiss). In some instances images were
acquired with a DeltaVision DV Elite microscope using an X100 objective. Image
analysis was carried out with FIJI (ImageJ) and Huygens Professional (Scientiﬁc
Volume Imaging) software.
Statistical analysis. In all immunoﬂuorescence experiments, a minimum of
50 ana/telophase cells per experiment were analysed in three independent
experiments. The w2-test was used to determine statistical signiﬁcance, unless
otherwise indicated in the ﬁgure legend.
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